184 related articles for article (PubMed ID: 31478424)
1. Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.
Jaiswal SR; Chakrabarti S
Immunotherapy; 2019 Oct; 11(14):1221-1230. PubMed ID: 31478424
[TBL] [Abstract][Full Text] [Related]
2. CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia.
Jaiswal SR; Bhakuni P; Joy A; Kaushal S; Chakrabarti A; Chakrabarti S
Biol Blood Marrow Transplant; 2019 Apr; 25(4):673-682. PubMed ID: 30610925
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study.
Jaiswal SR; Aiyer HM; Rawat G; Gera A; Chakrabarti S
Exp Hematol; 2019 Sep; 77():26-35.e1. PubMed ID: 31449833
[TBL] [Abstract][Full Text] [Related]
4. CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies.
Jaiswal SR; Bhakuni P; Bhagawati G; Aiyer HM; Soni M; Sharma N; Jaiswal RR; Chakrabarti A; Chakrabarti S
Bone Marrow Transplant; 2021 Jan; 56(1):185-194. PubMed ID: 32704091
[TBL] [Abstract][Full Text] [Related]
5. Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects.
Jaiswal SR; Chakraborty S; Lakhchaura R; Shashi P; Mehta A; Soni M; Chakrabarti S
Transplant Cell Ther; 2021 Feb; 27(2):144-151. PubMed ID: 33830023
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
7. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation.
Jaiswal SR; Bhakuni P; Bansal S; Aiyer HM; Bhargava S; Chakrabarti S
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e430-e435. PubMed ID: 31129111
[No Abstract] [Full Text] [Related]
9. Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation.
Jaiswal SR; Singhal P; Thatai A; Bhagwati G; Aiyer HM; Chakrabarti A; Chakrabarti S
Ann Hematol; 2020 Apr; 99(4):839-845. PubMed ID: 32025839
[TBL] [Abstract][Full Text] [Related]
10. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
Jaiswal SR; Bhakuni P; Bhagwati G; Aiyar HM; Chakrabarti A; Chakrabarti S
Transplantation; 2020 Jan; 104(1):e23-e30. PubMed ID: 31478993
[TBL] [Abstract][Full Text] [Related]
11. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
12. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
13. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
16. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
17. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
[TBL] [Abstract][Full Text] [Related]
18. HLA-haploidentical stem cell transplantation for hematologic malignancies.
Fuchs EJ; Huang XJ; Miller JS
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S57-63. PubMed ID: 19892024
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of T and NK cells after haploidentical hematopoietic cell transplantation using αβ T cell-depleted grafts and the clinical implication of γδ T cells.
Park M; Im HJ; Lee YJ; Park N; Jang S; Kwon SW; Park CJ; Choi ES; Koh KN; Seo JJ
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29090489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]